Listen: Relitigating Vioxx, industry growing pains, & how biotech VC works

Were we too hard on Vioxx? Are you still a disruptor if you have a lobbying budget? And how does venture capital work, exactly?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matthew Herper joins us to dig into the history of the infamous pain drug Vioxx and a new effort to bring it back as a rare disease treatment. Then, we discuss how the synthetic biology industry is growing up and getting corporate. Finally, health care journalist Maggie Fox dials in to explain her deep dive on venture capital in biotech.

For more on what we talk about, here’s the Vioxx news; here’s the latest from the world of synthetic biology; and here’s the report on VC in biotech.

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].